ArticleSmall (Weinheim an der Bergstrasse, Germany)2025
The Internal Nanostructure of Lipid Nanoparticles Influences Their Diverse Cellular Uptake Pathways.
Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Design of liquid crystalline nanoparticles: Linking composition to membrane interactions and siRNA delivery.International journal of pharmaceutics: X · 2026Article
- Liposomes can directly modulate serine hydrolase activity and lipid metabolism independent of cargo.Chemical science · 2026Article
- Beyond Exosomes: Biological Properties, Isolation Challenges, and Functional Redefinition of Non-Vesicular Extracellular Nanoparticles (NVEPs).Biomolecules · 2026Review
- Narrative Review of Nanomaterial Interactions in Plants with a Focus on Multi-Omics and Epigenetic Remodeling.Plants (Basel, Switzerland) · 2026Review
- A Copper-Complexing Lipid Unmasks the Ethanol Hidden Within Liposomes and Highlights the Relevance of Fabrication Method on the Performance of Lipophilic Functional Molecules.Small science · 2026Article
- Liquid crystalline mesophase spacing as a quantitative predictor of release kinetics for co-loaded hydrophilic and hydrophobic payloads.bioRxiv : the preprint server for biology · 2026Article
- In Vivo T-Cell Engineering: Revolution in Delivery Strategies and Clinical Translation.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Structural heterogeneity in mRNA-LNP subpopulations revealed by AF4-SAXS: implications for cargo loading and cell transfection.bioRxiv : the preprint server for biology · 2026Article
- Polyphenol-Mediated Engineering of Lipid Nanoparticles With Crystalline Mesophases.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- The Nanoparticle Delivery Gap in Immune Cell Engineering: From Uptake to Endosomal Escape.International journal of nanomedicine · 2026Review
- Lipid cubosome nanoparticles for drug delivery.Nanomedicine (London, England) · 2025Article
- Bypassing Endocytic Barriers: Visualizing Membrane Fusion and Endosomal Escape of Cubic Phase Lipid Nanoparticles (Cubosomes).Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- The Internal Nanostructure of Lipid Nanoparticles Influences Their Diverse Cellular Uptake Pathways.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid nanoparticles have emerged as critical platforms for bioactive agent delivery, with their success in COVID-19 vaccines highlighting the urgent need to address gaps in understanding their biological interactions. Lyotropic liquid crystalline nanoparticles (LLCNPs) represent promising nanocarriers for bioactive agent delivery. In this study, it is revealed for the first time how internal nanostructures of LLCNPs - liposomes, cubosomes, hexosomes, and micellar cubosomes - influence their cellular uptake pathways. By isolating the effects of mesophase while maintaining consistent particle size, charge, and surface coating, it is demonstrated that non-lamellar LLCNPs, particularly cubosomes, significantly enhance cellular uptake via distinct endocytic and non-endocytic mechanisms. These nanoparticles predominantly utilize passive non-endocytic pathways, such as membrane fusion, bypassing endocytic recycling challenges faced by most nanomaterials, including lamellar liposomes. Among active endocytic pathways, macropinocytosis emerges as the dominant route for non-lamellar particles. The findings establish a direct link between LLCNP internal nanostructure and cellular internalization mechanisms, highlighting the critical role of mesophase design in optimizing nanocarrier performance. This knowledge enables the rational engineering of LLCNPs tailored to target specific uptake pathways, facilitating precision delivery for diverse therapeutic applications and addressing key barriers in intracellular drug transport.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.